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Mediators produced by innate immune response cellssuch as macrophages can profoundly influence adap-tive immunity. Recent studies have shown that inter-
leukin (IL) 18 has an influential role in inflammatory
response. Recent data are presented illustrating the import-
ance of IL18 in the induction and perpetuation of chronic
inflammation during experimental and clinical rheumatoid
synovitis. These findings suggest that antagonists to IL18 may
have a role in the treatment of organ specific autoimmune
diseases.
There is currently considerable interest in the interactive
role of innate and adaptive immunity. A large number of
mediators have been implicated, particularly those derived
from the innate response that can drive the adaptive
immunity. In this short review, we will summarise the work
carried out in our laboratory on the roles of interleukin (IL) 18
in adaptive immune response and in perpetuating chronic
organ specific inflammatory reactions.We will focus primarily
on rheumatoid arthritis (RA). The processes that initiate and
perpetuate RA are currently unclear. Successful clinical
targeting of tumour necrosis factor (TNF) α therefore
represents an exciting and important advance, not only in
therapeutics but also in understanding the disease pathogen-
esis. However, non-responder or partial responder patients are
not uncommon, and inflammatory disease usually flares on
discontinuation of treatment.1 2 This carries significant patho-
genetic implications for existing disease models. Moreover, it
exemplifies the clinical necessity for generation of further
novel, pathogenesis led interventions. One approach to the
detection of novel synovial inflammatory pathways is to
establish events that regulate synovial TNFα production.
Recently, our group has explored the expression of novel cyto-
kine activities in RA synovial membrane that could perpetuate
inflammatory synovitis, in particular through modulation of T
lymphocyte function and TNFα expression by IL18, an innate
cytokine produced principally by macrophages after activation
by a range of stimuli, including infection and stress.
IL18
IL18 is an 18 kDa glycoprotein derived by enzymatic cleavage
of a 23 kDa precursor, pro-IL18, by at least caspase 1.3 Pro-IL18
expression is widespread, including monocyte/macrophages,
dendritic cells, Kupffer cells, keratinocytes, articular chondro-
cytes, synovial fibroblasts and osteoblasts, and within adrenal
cortex and pituitary gland.4 IL18 mediates bioactivity through
a heterodimeric receptor consisting of α and β chains which
are widely expressed on naïve T lymphocyte subsets, natural
killer cells, macrophages, neutrophils, and chondrocytes.
IL18Rα, characterised previously as IL1R related protein
(IL1Rrp), binds IL18 at relatively low affinity (in the range of
10−8 M). Generation of IL18Rα deficient mice confirmed that
this receptor is nevertheless essential for signalling.5 IL18Rβ
chain, initially termed IL1 receptor accessory protein-like
(AcPL), is related and similar to IL1RacP in that it does not
bind ligand directly, but rather binds to the complex formed by
the IL18-IL18Rα chain6 generating the likely high affinity
complex. Thus far, the signal transduction pathway known for
IL18R is identical with that of IL1R.
IL18 IN RA
We recently detected IL18 in the synovial compartment of
patients with RA.7 Whereas IL18 mRNA was found in synovial
membranes from patients with RA or osteoarthritis, IL18 pro-
tein was reproducibly detected by histology and enzyme
linked immunosorbent assay (ELISA) only in RA derived tis-
sues. IL18 expression was localised in RA synovial membranes
in cells of dendritic morphology within lymphocytic aggre-
gates and in lining layer areas. Subsequent double staining
confirmed expression in both CD68 macrophages and
fibroblast-like synoviocytes. Addition of IL18 consistently
induced production of TNFα, granulocyte/macrophage colony
stimulating factor, and interferon (IFN) γ by RA synovial
membrane or synovial fluid mononuclear cultures in vitro.
IL18 induced cytokine production was significantly enhanced
by coincident addition of IL12 and/or IL15, and suppressed by
IL10 and transforming growth factor β. That IL18 was acting
not only through lymphocyte activation, but also through
direct effects on macrophages was confirmed using intracellu-
lar cytokine staining.7 These data show that a primary
function of IL18 may be direct promotion of the synthesis of
TNFα through binding to macrophage IL18R. Importantly,
dose-response studies show that only very low concentrations
(down to 1 pg/ml) of IL15, IL18, or IL12 are required to induce
TNFα production in vitro. In contrast with IL15, we found that
IL18 activation of synovial T cells does not alter subsequent T
cell-macrophage interactions directly. However, addition of
recombinant IL18 to cytokine activated, formalin fixed T cell/
monocyte cocultures synergistically up regulates TNFα pro-
duction mediated through direct effects of IL18 on the target
monocyte population (unpublished observations). Thus IL18
synergistically and potently enhances the proinflammatory
potential of T cell-monocyte interactions, which are in turn
induced by IL15.
Factors regulating IL18 in synovial membrane are as yet
unclear. IL18 expression in monocytes is complicated by con-
stitutive expression of mRNA. IL18 mRNA and protein
expression are, however, up regulated in vitro in fibroblast-like
synoviocytes by IL1β and TNFα, suggesting the existence of
positive feedback loops linking the well recognised monokine
predominance with cytokine production and Th/c 1 cell
activation in synovial immune responses. Finally, IL18 also
induced nitric oxide release by RA synovial membranes in
vitro. As nitric oxide inhibits caspase 1 activity, this provides a
potential feedback loop, whereby IL18 may regulate its own
cleavage.4 8
IL18 IN EXPERIMENTAL ARTHRITIS
We then investigated the mechanism of IL18 induced arthritis
in vivo using a murine model of collagen induced arthritis
(CIA) in DBA/1 mice.9 Mice primed intradermally with type II
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Abbreviations: CIA, collagen induced arthritis; IFN, interferon; IL,
interleukin; RA, rheumatoid arthritis; RT-PCR, reverse
transcriptase-polymerase chain reaction; TNF, tumour necrosis factor
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bovine collagen and then boosted intraperitoneally 21 days
later with this type of collagen in saline developed a mild form
of CIA. The incidence and severity of the disease was consid-
erably increased when the mice were treated intraperitoneally
with 100 ng IL18/mouse/day from day −1 to 4 and then again
on days 20–24. The cytokine treatment led to significantly
enhanced synovial hyperplasia, cellular infiltration, and carti-
lage erosion compared with controls treated with phosphate
buffered saline. IL18 treated mice produced significantly more
IFNβ, TNFα, and IL6 than the controls. Furthermore, splenic
macrophages fromDBA/1mice cultured in vitro with IL18, but
not IL12, produced substantial amounts of TNFα. Together,
these results show that IL18 can promote CIA through
mechanisms that may be distinct from those induced by IL12.
To investigate directly the effect of endogenous IL18 expres-
sion, we generated IL18 deficient mice on a DBA/1 back-
ground. These mice developed appreciably delayed onset and
milder severity of CIA than wild type littermates. The reduced
disease is characterised by decreased TNFα concentrations in
serum and spleen cultures in vitro and by suppressed type II
collagen specific Th1 responses in vitro.10 Importantly, the
reduced CIA in the IL18 knockout mice can be reversed by the
administration of recombinant murine IL18. Compatible with
this, antibody mediated IL18 neutralisation suppressed strep-
tococcal cell wall induced arthritis through an IFNγ independ-
ent mechanism,11 and IL18BP-Fc fusion retarded established
CIA to an extent comparable to etanercept.12 Finally, we have
shown that antibody to IL18 suppressed development of
carrageenin induced paw inflammation by directly suppress-
ing TNFα expression,13 suggesting that IL18 can operate
upstream of TNFα production in vivo. Together, these data
strongly suggest that the net effect of IL18 expression is
proinflammatory, at least in antigen driven articular inflam-
mation.
SOLUBLE IL18Rα (sIL18Rα)
We have previously shown that soluble IL15Rα is a potent
antagonist of IL15 in vitro and significantly attenuated CIA in
DBA/1 mice.14 Building on this concept, we cloned a truncated
version of the extracellular domain of human IL18Rα using
reverse transcriptase-polymerase chain reaction (RT-PCR),
based on a published sequence of IL18Rα.15 mRNA from
human peripheral blood mononuclear cells stimulated with
Staphylococcus enterotoxin B was analysed with primers that
amplify the extracellular domain without the leading se-
quence. Unexpectedly, two PCR products were obtained. The
smaller fragment was the expected size for IL18Rα. The larger
fragment contained an extra 57 bp, inserted from bp 492 of the
human IL18Rα cDNA, suggesting that a novel exon may have
contributed to this larger IL18Rα mRNA. Using a Blasta-2
sequence search, this novel exon was matched 100% with a 57
bp sequence located in the human IL18Rα intron between
exon 3 and 4. We called this new exon, exon 3’. These results
also indicate that the novel human IL18Rα mRNA and previ-
ously reported membrane bound IL18Rα are transcribed by
differential splicing. Further analysis found a stop codon
(TGA) in the inserted coding region of the novel IL18Rα. As
this TGA would make a translational stop before the
transmembrane domain of IL18Rα, it is likely that this novel
fragment is a naturally produced soluble IL18Rα. Another
primer was then used to span the inserted region to clone out
this novel sIL18Rα. RT-PCR with primers WR1 and WR4 pro-
duced only a single band at the expected 400 bp. The novel
sIL18Rα was then expressed by transfecting COS-7 cells with
sIL18Rα fused with green fluorescent protein (GFP) and
tagged with myc/6×his under tetracycline induction. Trans-
fectants produced sIL18Rα-GFP detectable with anti-Myc as
well as anti-IL18R IgG by Western blot. Moreover, the soluble
product strongly suppressed IL18 induced IFNγ synthesis by
KG1 cells.
We then investigated whether sIL18Rα is secreted by
physiologically relevant cells. The human monocytic cell line,
KG1, was cultured in vitro with graded concentrations of
TNFα and mRNA, and culture supernatants were collected for
analysis. sIL18Rα was detected intracellularly and as secreted
protein in the culture supernatant in a time and dose depend-
ent manner. Further experiments show that, under different
activating conditions, humanmononuclear cells can produce a
number of spliced variants of sIL18Rα. For example, when
peripheral blood mononuclear cells were activated with
Staphylococcus enterotoxin B and IFNγ, six species of IL18Rα
with size ranging from 250 to 900 bp were detected by RT-PCR
Southern blot. The existence of spliced variants of cytokine
receptors has been observed previously. For example, three
isoforms of IL15Rα mRNA have been described that result
from alternative splicing of exon 3 and/or alternative usage of
exon 7 or 7’.16 More recently, eight further variants of IL15Rα
resulting from splicing of exon 2 have been identified.17 Natu-
ral spliced variants of cytokines have been studied extensively,
and some are found to have considerable inhibitory effects on
clinical inflammation.18 Biochemical studies have shown that
IL18Rα protein exists as heterogeneous molecules ranging
from 60 to 110 kDa, which could not be explained by deglyco-
sylation alone.19 Thus, there may be a family of spliced variants
of naturally produced sIL18Rα, possibly with distinct func-
tions in the regulation of IL18 activity for the maintenance of
immunological homoeostasis. Such molecules could be
exploited for treatment of inflammatory diseases associated
with the overexpression of IL18.
CONCLUSION
Our studies show the potential for striking cytokine synergy in
promoting synovial inflammation. Our choice of IL18, an IL1-
like cytokine (NF-κB dependent), and IL15, an IL2-like cyto-
kine (STAT3/STAT5 dependent), may partially explain this
synergism, although this remains to be explored. Enhanced
expression of IL15 and IL18 extends beyond RA to include
several human inflammatory diseases. Thus, the biological
activities elucidated here for IL18 will probably be of general
importance. The ultimate significance of IL18 expression in
autoimmune disease in vivo, however, requires confirmation
in humans before therapeutic intervention can be performed.
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